Partner Sites
Executive War College
The Dark Report
Dark Daily
G2 Intelligence
Trends
Events
Digital Forums
Webinars
Resources
Ebooks
Infographics
White Papers
Magazine
Login
Subscribe Today
Business & Policy
Advocacy & Professional Affairs
FDA, CMS & Regulatory Frameworks
IVD Market
M&A, Consolidation & Competitive Landscape
Market Trends & Business Intelligence
Payer Policy
Public Health & Population Testing Strategy
Lab Operations
Budgeting, Cost Control & Purchasing Strategy
Procurement & Vendor Alignment
Remote/Hub-and-Spoke Testing Networks
Revenue Cycle Management
Sustainability & Resource Efficiency
Workflow Optimization & Lean Lab Design
Workforce, Staffing & Training
Compliance
Biosafety, Biosecurity & Risk Management
CLIA, Regulatory, & Accreditation
Data Integrity & Traceability
Proficiency Testing & External QC
Quality Control & Quality Assurance
Validation, Verification & Method Comparison
Emerging Tech
Cell & Gene Therapy Diagnostic Interfaces
Digital Pathology, AI & Computational Diagnostics
Genomics, Proteomics, & Metabolomics
Liquid Biopsy & Early Detection
Precision Medicine & Companion Diagnostics
Tools & Techniques
Analyzers, Automation, & Diagnostic Platforms
Consumables & Lab Supplies
LIMS, Data Systems & Digital Workflows
Liquid Handling & Laboratory Robotics
Microscopy & Digital Pathology Imaging
PCR & qPCR Systems
Sample Prep & Processing Systems
Sequencing & Multiomics Platforms
Diagnostics & Testing
Clinical Chemistry
Hematology, Hemostasis, & Urinalysis
Microbiology & Infectious Disease
Molecular Diagnostics
Pathology & Histology
Point-of-Care Testing
Specimen Collection, Transport, & Pre-Analytical Processes
Toxicology & Pharmacology
Subscribe
Subscribe Today
Jane Theaker, MSc
Jane Theaker, MSc, is the CEO of PBD Biotech, a pioneer in the development of phage-based diagnostics for tuberculosis and related diseases.
Articles by Jane Theaker, MSc
Thought Leadership
|
3 min read
Can Phage-Based Diagnostics End the Global TB Rage?
Natural mechanisms of bacteriophages may help identify active TB early in those at risk
by
Jane Theaker, MSc
Page 1 of 1
1
Sponsored
Bridging Vision and Execution: A Candid Conversation on the Future of the Laboratory
Sponsored by
Your Model From Our Experience: Cloud First Digital Pathology in a High-Volume Regional Laboratory
Sponsored by
Ensuring Compliance: How to Get AI Diagnostic Tools Approved for Clinical Practice
Sponsored by
Cutting-Edge Gastrointestinal Pathogen Testing Technologies for Labs
Sponsored by
